Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSS: Sulfonylurea Safety and Effectiveness for Patients With Hyperglycemia and Pancreatic Ductal Adenocarcinoma
NCT06168812Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glipizide in hyperglycemia (3 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Change in mean interstitial glucose level at 48 hours. Started Dec 2023; status: active, not recruiting.
02
Drugs
glipizide
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT06168812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168812.